Table 2.

Patients’ characteristics, treatment procedure and response to treatment of patients included in control group

Patient	Gender	Age (years)	Creatinine (μmol/L)	Total bleomycin dose (IU)	Electrodes used	Last follow-up (months after ECT)	Histology	Maximum tumor size (mm)	Recurrence of tumor (months after ECT)
1	M	65	68	30,000	Needle row	39	BCC	22
2	F	74	86	26,000	Needle row	55	BCC	15
3	M	83	129	28,000	Plate	19 *	BCC	12
							BCC	32	7
							BCC	10	7
4	M	81	78	27,000	Needle row	37	BCC	10
							BCC	5
							BCC	6
							BCC	4
5	F	82	73	24,000	Plate	41	BCC	9	6
							BCC	5
							BCC	11
6#	M	88	142	30,000	Plate	2	BCC	39
7	F	69	84	23,000	Finger	46	BCC	15
8	F	82	DM	24,000	Hexagonal	41	BCC	50
							BCC	7
							BCC	20	18
9	F	89	69	23,000	Plate	48	BCC	6
							BCC	5
							BCC	6
10	M	65	DM	27,000	Plate	31	BCC	24
11#	F	70	DM	27,000	Plate	4	BCC	7
12	M	78	DM	23,000	Plate	46	BCC	15
13	F	74	52	24,000	Needle row	38	BCC	15
14	F	89	54	25,000	Plate	48	BCC	21
								BCC	22
15	M	67	DM	30,000	Plate	11	SCC	25
16	M	85	100	24,000	Needle row	15 *	SCC	45

BCC = basal cell carcinoma; ECT = electrochemotherapy; F = female, M = male; SCC = squamous cell carcinoma; ^* = patient deceased; # = excluded from analysis